Welcome to our dedicated page for IPERIONX SEC filings (Ticker: IPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IPERIONX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IPERIONX's regulatory disclosures and financial reporting.
IPERIONX Ltd (IPX) reports that the U.S. Army has issued Task Order 2 under its Small Business Innovation Research (SBIR) Phase III IDIQ contract for low-cost domestic titanium. The SBIR Phase III contract allows project-specific orders collectively capped at US$99 million.
Task Orders 1 and 2 have an aggregate stated value of about US$19.8 million, leaving US$79.2 million available under the ceiling. Task Order 2 is a firm-fixed-price order with a base value of US$18.5 million, of which US$11.5 million is currently funded and obligated. Unexercised options of US$6.9 million could bring its maximum potential value to US$25.4 million.
The funding supports equipment and systems to expand IperionX’s U.S. titanium powder-to-part manufacturing capacity, including continuous HSPT™ and dehydrogenation furnaces and in-house fastener finishing at its Virginia facility. Option items, if exercised, could extend its patented HAMR™ and HSPT™ technologies into aerospace components and refractory-metal (C103 and niobium) powder programs.
IPERIONX Ltd reported the initial equity holdings of new director Michael J. Loparco. Upon joining the board on August 3, 2026, he received a sign-on grant of 58,584 Restricted Stock Units (RSUs). According to the disclosure, these RSUs vest on August 3, 2027, and are currently reported as directly owned holdings.
IperionX Limited intends to pursue a redomiciliation under which a newly incorporated Texas corporation would become the ultimate parent company of the group. The proposal is subject to shareholder, court, regulatory, exchange and other customary approvals. Subject to final structuring and approvals, the common stock of the new U.S. parent is expected to list directly on Nasdaq, replacing the existing ADS structure. The company states that the redomiciliation is intended to align its American operating footprint, customers and government-supported programs with an American legal and capital-markets structure, and is not expected to change underlying assets, operations or strategic priorities.
IperionX has also appointed Michael J. Loparco as an independent non-executive director, effective August 3, 2026. He brings more than 25 years of leadership experience across advanced manufacturing, industrial technology, automation, global supply chains and public-company governance, including senior roles at Symbotic Inc. and Jabil Inc. IperionX describes itself as an American titanium metal and critical materials company using patented technologies to produce high-performance titanium alloys and developing the Titan critical minerals project in the United States.
IperionX Limited advanced its U.S.-based titanium and critical minerals strategy for the quarter ended June 30, 2026. Titanium powder and component operations in Virginia ran on a 24/7 schedule, with commissioning of a 300-ton SACMI press that triples powder metallurgy capacity and installation of new HSPT™ furnaces to ease downstream bottlenecks. Customer programs progressed, including titanium impeller prototypes for Carver Pump, track-pin development and fastener work supported by U.S. Army testing.
In Tennessee, a U.S. Government-supported Definitive Feasibility Study for the Titan Critical Minerals Project outlined an after-tax NPV8 of US$813 million, a 39.4% after-tax IRR and staged capital of US$228.1 million for Phase 1 and US$153.2 million for Phase 2. IperionX completed the US$3 million Atlas acquisition adjacent to Titan, adding high-grade stockpiles and infrastructure, with an integrated Atlas-Titan economic study targeted by the end of 2026.
U.S. Government support totals US$59.8 million in DPA Title III and IBAS awards, with US$22.7 million reimbursed and US$37.1 million remaining reimbursable, plus an SBIR Phase III contract pathway up to US$99 million. Cash was US$35.2 million at June 30, 2026, with pro-forma cash of about US$84 million after a July underwritten public offering of 2,275,000 ADSs at US$21.98 per ADS for approximately US$50 million in gross proceeds and a US$2.4 million DPA Title III reimbursement; net cash used in operating activities was US$11.9 million for the quarter.
IPERIONX Ltd director Beverly Wyse exercised options to acquire 106,093 IPX Ordinary Shares at 0.8700 in Australian dollars per share that were exercisable until December 5, 2026. After the exercise she directly holds 745,868 ordinary shares plus 84,771 RSUs, with 70,609 vesting in December 2026 and 14,162 in December 2027; no open‑market sale is reported.
IPERIONX Ltd director R Tony Tripeny bought 3,846 American Depository Shares (ADS) on July 14, 2026 at $26 per ADS in an open-market purchase. After the trade, he directly holds 8,033 ADS, 51,010 Restricted Stock Units and 38,777 IPX ordinary shares.
IPERIONX Ltd director Lorraine M. Martin purchased 4,100 American Depository Shares (ADS) of IPX at $24.51 per ADS in an open-market transaction on July 10, 2026. Following the trade, she holds 8,855 ADS, 1,177,138 ordinary shares and 90,216 RSUs, with 76,054 RSUs vesting in December 2026 and 14,162 in December 2027. Each ADS is equivalent to 10 ordinary shares.
IPERIONX Ltd President Toby Edgcumbe Symonds reported an open-market purchase of 2,040 American Depository Shares (ADS) of IPX at $24.55 per ADS, representing 20,400 Ordinary Shares. Following this trade, he holds 39,040 ADS, equivalent to 390,400 Ordinary Shares, plus 3,128,089 IPX Ordinary Shares directly. He also holds 703,199 RSUs and a substantial package of options and performance rights over additional Ordinary Shares at exercise prices between A$4 and A$22, with expirations between 2028 and 2031.
IPERIONX Ltd Chief Executive Officer Anastasios Arima reported an open-market purchase of 138,720 IPX Ordinary Shares on July 10, 2026 at an average price of A$3.5844 per share, bringing his directly held Ordinary Shares to 12,455,502. He also directly holds 738,576 Restricted Stock Units, multiple option and performance-right awards over Ordinary Shares at exercise prices between A$6 and A$22, and 128,000 American Depository Shares (ADS), each ADS representing ten Ordinary Shares.
IPERIONX Ltd Executive Chairman Todd Hannigan reported open-market purchases of IPX Ordinary Shares. He bought 225,000 shares on July 10, 2026 at an average price of $3.5786 per share and 300,000 shares on July 13, 2026 at $3.5866 per share, for total recent purchases of 525,000 shares. Following these transactions, he directly holds 26,633,334 Ordinary Shares, along with 454,464 RSUs, 500,000 ADS (each ADS convertible into 10 Ordinary Shares), and various options and performance rights over additional Ordinary Shares.